AxoGen has raised $12.1 million in series C funding from Accuitive Medical Ventures, Cardinal Partners, De Novo Ventures and Springboard Capital II.
Subscribe to our email newsletter
In July 2007, AxoGen established itself in the nerve regeneration field with the launch of Avance nerve graft for peripheral nerve repair.
Jamie Grooms, CEO and co-founder of AxoGen, said: “This round of funding will enable us to provide the Avance nerve graft to more surgeons, giving them a new solution to repair and regenerate peripheral nerves.”
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.